Targeted gene screening allowed us to identify additional pathogenic variants in RASAL1 and ROS1. In particular, we found a significant increase in the number of ROS1-mutated individuals in BC cases (131), compared to population controls (197 Italian individuals). This evidence concerns the gene RASAL1 and breast cancer.